First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher)

Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University Hospital in Essen, Germany. weiter


Personnel Changes in the Management of Eckert & Ziegler AG

Changes in the Executive Board and Supervisory Board weiter


Cambrium Secures €8 Million in Seed Funding to Commercialize New Class of Performance Molecules

Synthetic biology startup Cambrium announces €8 Million in Seed financing, led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital. Seed financing will drive commercial growth for Cambrium’s first product, NovaColl™, and accelerate expansion into new industries weiter


Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177. weiter


Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets

The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. A separate decision will be taken at a later date on the specific start and the manner of the exit. In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. PTX also includes Myelo Therapeutics GmbH. weiter


Boost for Berlin’s biotech sector

Campus Berlin-Buch has a new start-up center: The BerlinBioCube was ceremonially opened on October 11, 2023 in the presence of the Governing Mayor. weiter


Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma

Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today signed an agreement with POINT Biopharma Global Inc. ("POINT", NASDAQ: PNT) for the supply of carrier-free lutetium-177 (n.c.a.177Lu). The agreement has a term of ten years with a total sales volume of more than € 100 million. weiter


Starting up with highly promising immunotherapies

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable. weiter


Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to jointly develop a new concept – Satellite Hot Labs (SHLs). SHLs are designed specifically for radiolabeling, quality control and storage of molecular targeting radiotracers, referred to as BioGuides, that are used in biology-guided radiotherapy (BgRT) to direct the radiation beam to indicated solid tumor cancers. weiter


New muscle therapy gets fast-track boost

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall. weiter


Biosynth Expands Capabilities with Acquisition of celares, Experts in Bioconjugation and Specialty Polymers

Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer based drug delivery excipients. weiter


OMEICOS Therapeutics Receives 2.5 million Euros in Grant Funding Supporting OMT-28’s Development in Mitochondrial Diseases Through a Phase 2a Clinical Study

OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28*. The funding provided under the “KMU-innovativ: Biomedizin” program will be used to co-finance the upcoming Phase 2a clinical study evaluating OMT-28 in Primary Mitochondrial Disease (PMD) patients. The study will be conducted in leading European clinical centers for mitochondria-related pathologies. In April 2023, OMEICOS had received first approvals of the study design from the respective regulatory authorities. weiter


Interview about Berlin-Buch – A Location for Future Innovation

The BerlinBioCube incubator is currently being built on Campus Berlin-Buch. The new five-story building provides a total of 8,000 m² of space for state-of-the-art laboratories, offices, and shared spaces. |transkript spoke to the Managing Director. weiter


T-knife Therapeutics Presents Preclinical Data on the Anti-Tumor Activity of TK-8001 at ISCT Annual Meeting

T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing T cell receptor-based immunotherapies that deliver transformational benefits to cancer patients, today announced presentation of a poster titled, ”MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to human-derived MAGE-A1 TCRs” at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held from May 31 – June 3, 2023 in Paris, France. weiter


Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry players to dive into a vigorous discussion on the central topics of the rapidly developing radiotheranostics market. The Forum will discuss solutions to challenges in supply chain, upscaling and patient access as well as the latest theranostic concepts. weiter


Reorganization in the Executive Board of Eckert & Ziegler

The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from their positions at the end of the Annual General Meeting on June 7, 2023, by mutual agreement. Their responsibilities and the chairmanship of the Executive Board will be taken over by the current Chief Sales Officer of the Medical segment, Dr. Harald Hasselmann. Newly appointed to the Executive Board and responsible for the Isotope Products segment will be Frank Yeager, the longtime head of this California based business unit. The positions of Dr. Hakim Bouterfa and Jutta Ludwig on the Management Board remain unaffected by the changes. weiter


Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as inflation adjustments. weiter


Berlin-Buch goes BIO International Convention

The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships. One of the companies attending is Campus Berlin-Buch GmbH. weiter


Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority. The approval is the basis for the marketing authorization of Lutetium-177 as a drug, but also for use of this radioisotope as a starting material for the manufacture of radiopharmaceuticals. By making Lutetium available to a significantly broader range of users, the approval will enable Eckert & Ziegler to further continue its successful strategy as one of the world leading isotope suppliers. weiter


Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces the successful completion of a Series A extension financing, raising a further EUR 22.75 million, following the EUR 25 million Series A financing announced in June 2022. The financing was co-led by new investors Andera Partners and Earlybird Venture Capital, with participation from existing investor Pureos Bioventures, now doubling its original investment in the Company. As part of the investment, Olivier Litzka, Partner at Andera Partners, and Christoph Massner, Principal at Earlybird, will join the Ariceum Board of Directors. weiter


CELLphenomics’ and KYAN Therapeutics combined platforms provide best-in-class solutions to support the biopharma industry

CELLphenomics and KYAN Therapeutics announced their new partnership today. By combining KYAN's technology platform, Optim.AI™ - which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics' proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry. The combination of these two unique technologies will allow reliable conclusions about the treatability of the tumor and its functional causes of therapeutic success and/or failure, leading to novel treatment combinations and faster preclinical development of new anti-cancer drugs. weiter


Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands. weiter


Long awaited by the pharma industry

It takes great patience and perseverance to turn research findings into new technologies or therapies. The Helmholtz Initiative and Networking Fund gives financial support to “pathfinder projects” that are particularly promising. Researchers at the Max Delbrück Center have now won grants for three projects. weiter


Eckert & Ziegler Plans Change of Legal Form to European Stock Corporation (SE)

The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing its legal form. The dualistic management system, consisting of an Executive Board as the management body and a Supervisory Board as the supervisory body, is also to continue under the SE legal form. Responsibilities and composition of the executive board and supervisory board remain unaffected by the new structure. The registered office of the company shall continue to be in Berlin. weiter

Colors of BerlinBioCube